Results 211 to 220 of about 50,964 (281)

HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer. [PDF]

Cell Death Dis
Yanushko D, Pichot A, Vincent A, Keime C, Laverny G, Metzger D.   +5 more
europepmc   +1 more source

Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer. [PDF]

BMC Cancer
Lapointe-Belleau A, Rouleau M, Villeneuve L, Descarreaux J, Caron P, Beaudoin C, Uchil A, Simonyan D, Dahmani C, Joly-Beauparlant C, Gélinas V, Droit A, Marcoux N, Castonguay V, Lacombe L, Lévesque É, Guillemette C.   +16 more
europepmc   +1 more source

Molecular insights into DDX3X-androgen receptor mRNA regulation via non-canonical G-quadruplex in castration-resistant prostate cancer. [PDF]

Oncogene
Zhang H, Liu TT, Wu F, Colah AN, Ricke EA, Li L, Putnam AA, Ricke WA.   +7 more
europepmc   +1 more source

A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer. [PDF]

Oncologist
Graff JN, Smith CEP, Sokolova AO, Qian DZ, Beer TM, Latour E, Bailey S, Kreitner D, Grivas P, Schweizer MT, Higano CS, Alumkal JJ, Vuky J, Yu EY, Cheng HH.   +14 more
europepmc   +1 more source

From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. [PDF]

Drugs Real World Outcomes
Bosch D, van der Velden KJM, Beeker A, van den Berg HP, Bergman AM, van der Doelen MJ, van den Eertwegh AJM, Hendriks MP, Kerkhofs TMA, van de Luijtgaarden ACM, Mehra N, van Moorselaar RJA, Tascilar M, Vervenne WL, Weijl NI, Uyl-de Groot CA, Mulders PFA, Kuppen MCP, van Oort IM.   +18 more
europepmc   +1 more source

Correction: SLC7A11 upregulation via AR and NEDD4L ubiquitination contributes to ferroptosis inhibition and enzalutamide resistance in castration-resistant prostate cancer. [PDF]

Cell Death Dis
Tang M, Xue L, Wang B, Jiang Z, Li P, Bu H, Zhao C, Zhang Y, Liu S, Chen X, Liu B, Meng X, Li J.   +12 more
europepmc   +1 more source

Rethinking combination strategies in metastatic castration-resistant prostate cancer (mCRPC)-lessons from KEYNOTE-641. [PDF]

Transl Androl Urol
Nguyen MD, Vinh-Hung V, Verschraegen C, Wang P.   +3 more
europepmc   +1 more source